4-[5-(4-Fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[5-(4-Fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenoic acid
• 英文别名: (Z)-4-[5-[(4-fluorophenyl)methyl]furan-2-yl]-2-hydroxy-4-oxobut-2-enoic acid
• 化学式: C₁₅H₁₁FO₅
• 分子量: 290.248
• InChiKey: YQLIKHOIOMSJLF-JYRVWZFOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Antiviral agent
  申请人：——

  公开号：US20040229909A1

  公开（公告）日：2004-11-18

  The present invention provides an integrase inhibitor. The inventors have have found the following compound of formula (I) possessing an integrase inhibitory activity. 1 (wherein, R C and R D taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxy, mercapto or amino; Z is O, S or NH; R A is a group shown by 2 (wherein, C ring is N-containing aromatic heterocycle) or the like)

  本发明提供了一种整合酶抑制剂。发明人发现以下化合物具有整合酶抑制活性，其化学式为(I)。其中，RC和RD与相邻的碳原子一起形成一个环，该环可以是一个缩合环，Y是羟基，巯基或氨基; Z是O，S或NH; RA是由2所示的基团（其中，C环是含N的芳香杂环）或类似基团。
• Heteroaromatic derivatives having an inhibitory activity against HIV integrase
  申请人：——

  公开号：US20040002485A1

  公开（公告）日：2004-01-01

  A compound of the formula (I): 1 wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is —COOR A wherein R A is hydrogen or ester residue, —CONR B R C wherein R B and R C each is independently hydrogen or amide residue, optionally substituted aryl or optionally substituted heteroaryl; and A 1 is optionally substituted heteroaryl; provided that a compound wherein Y and/or A 1 is optionally substituted indol-3-yl is excluded, a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof has an inhibitory activity against an integrase.

  式(I)的化合物：其中X为羟基，保护羟基或可选取代的氨基；Y为—COORA，其中RA为氢或酯基残基，—CONRBRC，其中RB和RC各自独立地为氢或酰胺基残基，可选取代的芳基或可选取代的杂芳基；且A1为可选取代的杂芳基；但其中Y和/或A1为可选取代的吲哚-3-基的化合物被排除，其互变异构体、前药、药物可接受的盐或水合物具有对整合酶的抑制活性。
• AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1142872A1

  公开（公告）日：2001-10-10

  A compound of the formula (I): wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is COORA wherein RA is hydrogen or ester residue, -CONRBRC wherein RB and RC each is independently hydrogen or amide residue, optionally substituted aryl or optionally substituted heteroaryl; and A1 is optionally substituted heteroaryl; provided that a compound wherein Y and/or A1 is optionally substituted indol-3-yl is excluded, a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof has an inhibitory activity against an integrase.

  一种式（I）化合物： 其中 X 是羟基、受保护的羟基或任选取代的氨基；Y 是 COORA（其中 RA 是氢或酯残基）、-CONRBRC（其中 RB 和 RC 各自独立地是氢或酰胺残基）、任选取代的芳基或任选取代的杂芳基；以及 A1 是任选取代的杂芳基；条件是其中 Y 和/或 A1 是任选取代的吲哚-3-基的化合物除外，其同分异构体、原药、药学上可接受的盐或水合物对整合酶具有抑制活性。
• Antiviral Agent
  申请人：SHIONOGI & CO., LTD.

  公开号：EP2181985A1

  公开（公告）日：2010-05-05

  The present invention provides an integrase inhibitor. The inventors have have found the following compound of formula (I) possessing an integrase inhibitory activity. (wherein, RC and RD taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxy, mercapto or amino; Z is O, S or NH ; RA is a group shown by (wherein, C ring is N-containing aromatic heterocycle) or the like)

  本发明提供了一种整合酶抑制剂。本发明者发现了以下具有整合酶抑制活性的式 (I) 化合物。 (其中，RC 和 RD 与邻近的碳原子共同形成一个环，该环可以是缩合环；Y 是羟基、巯基或氨基；Z 是 O、S 或 NH； RA 是以下所示的基团 (其中，C 环为含 N 的芳香杂环）或类似物）。
• ANTIVIRAL AGENT
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1422218B1

  公开（公告）日：2012-03-21